About Tyrosine-protein phosphatase non-receptor type 18
Tyrosine-protein phosphatase non-receptor type 18 (PTPN18) is a protein
from Homo sapiens identified by UniProt accession
Q99952, 460 residues long.
MolForge cross-references it against 0 known binders and
167 disease associations.
Target properties
| Protein name | Tyrosine-protein phosphatase non-receptor type 18 |
| UniProt accession | Q99952 |
| Gene | PTPN18 |
| Organism | Homo sapiens |
| Length | 460 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (167)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.48
- Alzheimer disease · score 0.27
- lysosomal storage disease · score 0.27
- multiple sclerosis · score 0.27
- Parkinson disease · score 0.27
- glioblastoma multiforme · score 0.24
- low grade glioma · score 0.11
- cancer · score 0.08
- glioblastoma · score 0.07
- familial atrial fibrillation · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q99952-F1 | alphafold | PREDICTED | 76.49 | — |
Amino-acid sequence (460 residues)
MSRSLDSARS FLERLEARGG REGAVLAGEF SDIQACSAAW KADGVCSTVA GSRPENVRKN RYKDVLPYDQ TRVILSLLQE EGHSDYINGN FIRGVDGSLA YIATQGPLPH TLLDFWRLVW EFGVKVILMA CREIENGRKR CERYWAQEQE PLQTGLFCIT LIKEKWLNED IMLRTLKVTF QKESRSVYQL QYMSWPDRGV PSSPDHMLAM VEEARRLQGS GPEPLCVHCS AGCGRTGVLC TVDYVRQLLL TQMIPPDFSL FDVVLKMRKQ RPAAVQTEEQ YRFLYHTVAQ MFCSTLQNAS PHYQNIKENC APLYDDALFL RTPQALLAIP RPPGGVLRSI SVPGSPGHAM ADTYAVVQKR GAPAGAGSGT QTGTGTGTGA RSAEEAPLYS KVTPRAQRPG AHAEDARGTL PGRVPADQSP AGSGAYEDVA GGAQTGGLGF NLRIGRPKGP RDPPAEWTRV
Explore Tyrosine-protein phosphatase non-receptor type 18 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets